论文部分内容阅读
目的:研究葛根素在大鼠体内的药动学过程以及维拉帕米对葛根素在大鼠体内药动学过程的影响。方法:对大鼠分别单独静注、单独口服葛根素溶液,联合静注、口服葛根素和维拉帕米溶液,采用高效液相色谱法测定葛根素在大鼠体内的血药浓度。结果:注射合用后,维拉帕米在低剂量时(0.5μg.g-1)对葛根素的药动学过程无显著性影响,但在高剂量时(2.5μg.g-1)有显著性影响(P<0.05)。口服合用后,维拉帕米对葛根素的药动学过程有显著性影响(P<0.05)。结论:葛根素与维拉帕米合用时,在一定浓度范围内,维拉帕米可抑制葛根素从大鼠体内的消除;二者合并用药时应对葛根素进行临床给药监测。
Objective: To study the pharmacokinetics of puerarin in rats and the effect of verapamil on the pharmacokinetics of puerarin in rats. Methods: Rats were given intravenous injection of puerarin alone, combined with intravenous injection, oral puerarin and verapamil solution. The plasma concentrations of puerarin in rats were determined by high performance liquid chromatography. RESULTS: Verapamil had no significant effect on the pharmacokinetics of puerarin at low doses (0.5μg.g-1) after injection, but at high doses (2.5μg.g-1) Sexual effects (P <0.05). After oral administration, verapamil had a significant effect on the pharmacokinetics of puerarin (P <0.05). Conclusion: When puerarin is combined with verapamil, verapamil can inhibit the elimination of puerarin from rats in a certain concentration range. The combination of puerarin and verapamil should be monitored clinically.